The drug could cost women as much as $400 per month

Valeant Pharmaceuticals agreed to pay about $1 billion (€895 million) in cash for Sprout Pharmaceuticals, the US pharmaceutical group that this week r(...)

Valeant Pharmaceuticals, the Canadian drugmaker known for its serial acquisitions, reported first-quarter profit that topped analysts’ estimates and r(...)

Teva factory sign on its plant in Jerusalem: Teva says its stock-and-cash offer of $82 a share represented a 48 per cent premium to Mylan’s stock price on March 10th, which it said was the last day of trading prior to the widespread speculation. Photograph: Menahem Kahana

Generic drugmaker Teva Pharmaceutical Industries Ltd yesterday proposed buying Mylan for $40 billion, saying it was a better deal than the smaller riv(...)

In Dublin Ryanair rose by more than 1.3 per cent as investors greeted the news that its board has ratified a push into the transatlantic market in coming years

Germany’s Dax raced to record highs on Monday, part of an extended rally of the European stock market driven by investors’ expectations that a weaken(...)

Michael “Mike” Pearson, chairman and chief executive officer of Valeant Pharmaceuticals International. It increased its offer for US based Salix Pharmaceuticals to $10.96 billion in cash, topping Dublin based Endo International’s bid of $10.93 billion. (Photograph: Scott Eells/Bloomberg)

Valeant Pharmaceuticals International said it increased its offer for US based Salix Pharmaceuticals to $10.96 billion in cash, topping Dublin based E(...)

Bausch & Lomb is the largest private sector employer in the southeast.

Eye-care company Bausch & Lomb is to create 50 new jobs over the next 18 months as part of a €41 million investment at its Waterford facility.The (...)

Valeant had said it was willing to pay at least $200 a share and has the backing of Allergan’s largest shareholder -- activist investor Bill Ackman’s (pictured) Pershing Square Capital Management LP. ( Photograph: Scott Eells/Bloomberg)

Actavis has agreed to pay about $66 billion (€52.6bn) for Allergan, after the maker of Botox turned to the drugmaker to repel a hostile advance from V(...)

A doctor injects a patient with Allergan’s Botox. Photographer: Patrick T. Fallon/Bloomberg

Botox maker Allergan, which is fending off an acquisition by Valeant Pharmaceuticals, said today that it had been approached by another party regardi(...)

Botox producer Allergan  is resisting Valeant’s hostile offer. Photograph: Shannon Stapleton/Reuters

Valeant Pharmaceuticals said in a letter yesterday to Allergan’s board of directors that it was prepared to raise its offer to at least $200 per share(...)

 Allergan shareholder Paulson & Co is said to be urging the Botox maker to merge with specialty pharmaceutical company Shire. Photo: Eric Luke/The Irish Times

Allergan shareholder Paulson & Co is said to be urging the Botox maker to merge with specialty pharmaceutical company Shire as an alternative to (...)